|Assessment Status||Rapid Review Complete|
|Indication||Dupilumab (Dupixent®) is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.|
|Rapid review commissioned||24/07/2023|
|Rapid review completed||05/09/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.